Dynamk Capital

Dynamk Capital investment thesis

Portfolio News CONTACT US Scroll Funding the Future of Life Sciences News News February 24, 2026 bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub February 24, 2026 Read more → February 24, 2026 December 11, 2025 Xcell Biosciences and Culture Biosciences Announce AI/ML Partnership for Cell Therapy December 11, 2025 Read more → December 11, 2025 October 8, 2025 Alpenglow Biosciences and Virdx Announce Strategic Deal to Advance AI-Enabled Prostate Cancer Diagnostics October 8, 2025 Read more → October 8, 2025 October 7, 2025 RoosterBio & Secretome Therapeutics Announce Successful Completion of Large Scale Production for Clinical Stage Cell Therapy Candidate October 7, 2025 Read more → October 7, 2025 October 1, 2025 ZEISS and Alpenglow Biosciences U

Dynamk Capital team (2)

Partners and principals at Dynamk Capital:

• Gustavo Mahler — sweet spot $1.5M
• Reinhard Vogt — sweet spot $1.5M

Dynamk Capital portfolio companies

Companies listed on Dynamk Capital's public materials include: Portfolio, News, Alpenglow Biosciences Launches New Software Platform, The Future of Pathology, Integrating Human Cells, Systems, and Data, REAL-TIME CELL ANALYSIS, Exits, ACOUSTIC CELL HANDLING, Portfolio Intro, Portfolio News, Portfolio Companies, Disclaimer.

Is Dynamk Capital a fit for your round?

Upload your pitch deck and see whether anyone at Dynamk Capital appears in your top matches.